Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332253 | 0.88 | NR1H2 (0.42) | USP30NR1H2NR1H3KMT2AUSP2 | |
| SCHEMBL30545389 | 0.87 | NR1H2 (0.40) | USP30NR1H2NR1H3KMT2AUSP2 | |
| SCHEMBL25333214 | 0.87 | NR1H2 (0.41) | USP30NR1H2NR1H3KMT2AUSP2 | |
| SCHEMBL26987927 | 0.84 | USP30 (0.47) | USP30NR1H2NR1H3KMT2ALMNA | |
| SCHEMBL31290628 | 0.84 | USP30 (0.47) | USP30NR1H2NR1H3KMT2ALMNA | |
| SCHEMBL25331015 | 0.83 | KDM1A (0.38) | KMT2ALMNAAAK1 | |
| SCHEMBL29443596 | 0.82 | NR1H2 (0.45) | USP30NR1H2NR1H3USP2SMN1; SMN2 | |
| SCHEMBL22807082 | 0.82 | NR1H2 (0.45) | USP30NR1H2NR1H3USP2SMN1; SMN2 | |
| SCHEMBL21682785 | 0.82 | NR1H2 (0.50) | NR1H2NR1H3KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL25332697 | 0.81 | USP30 (0.40) | USP30NR1H2NR1H3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4466072-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | Almac Discovery Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| CN-118946566-A | Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors | 阿尔麦克探索有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023139241-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | USP30 31/4885NR1H2 3986/4885NR1H3 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.